GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance
- 17 October 2025
- journal article
- review article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 789, 152822
Abstract
No abstract availableKeywords
This publication has 204 references indexed in Scilit:
- Intestinal intraepithelial lymphocytes: Maintainers of intestinal immune tolerance and regulators of intestinal immunityJournal of Leukocyte Biology, 2020
- The GLP‐1 receptor agonist liraglutide protects against oxidized LDL‐induced endothelial inflammation and dysfunction via KLF2IUBMB Life, 2019
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2017
- Role of Epicardial Adipose Tissue in Health and Disease: A Matter of Fat?Comprehensive Physiology, 2017
- Liraglutide for weight management: a critical review of the evidenceObesity Science & Practice, 2016
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetesDiabetologia, 2011
- RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cellsDiabetologia, 2010
- Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling PathwayHepatology, 2010
- Elevation of Intracellular Cyclic AMP Induces an Anergic-like State in Th1 ClonesCellular Immunology, 1996
- Glucagon-like Peptide-1 Modulates Ca2+ Current But Not K+ATP Current in Intact Mouse Pancreatic B-CellsBiochemical and Biophysical Research Communications, 1995